title: Human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) infection in men receiving treatment for HIV-1 infection.
abstract: OBJECTIVE
  To determine the prevalence of human herpesvirus 8 (HHV-8) infection in men treated for HIV-1 infection in Denver, Colorado.
  
  
  METHODS
  Cross-sectional analysis
  
  
  METHODS
  Blood samples were obtained from 216 HIV-1-infected men. Antibody to latency-associated nuclear antigen (LANA) was detected by an immunofluorescent assay and the presence of HHV-8 in peripheral blood mononuclear cells (PBMC) was detected by polymerase chain reaction amplification.
  
  
  RESULTS
  Among HIV-1-infected men who did not have Kaposi's sarcoma (KS), prevalence of HHV-8 infection was 46% (95% confidence interval [CI], 0.39-0.52). LANA seropositivity was common both among subjects with KS and subjects without KS (69% versus 42%; p = .06), but detection of HHV-8 DNA in peripheral blood was strongly associated with a diagnosis of KS (44% versus 10%; p = .001). In a univariate analysis of study subjects without KS, neither the odds of LANA seropositivity nor detection of HHV-8 DNA in PBMC was significant for CD4+ lymphocyte count, HIV-1 virus load, the use of three drug antiretroviral regimens or the prior occurrence of non-KS AIDS-related conditions.
  
  
  CONCLUSIONS
  Although antibodies to HHV-8 are common among HIV-1-infected men, detection of HHV-8 DNA in PBMC is uncommon and is associated with a diagnosis of Kaposi's sarcoma.
authors.affiliation: Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA.
authors.forename: T B
authors.initials: TB
authors.lastname: Campbell
authors.forename: L
authors.initials: L
authors.lastname: Fitzpatrick
authors.forename: S
authors.initials: S
authors.lastname: MaWhinney
authors.forename: X
authors.initials: X
authors.lastname: Zhang
authors.forename: R T
authors.initials: RT
authors.lastname: Schooley
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000453:epidemiology* / Q000821:virology; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral; D003430:Cross-Sectional Studies; D004279:DNA, Viral / Q000097:blood; D005455:Fluorescent Antibody Technique; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000302:isolation & purification; D006566:Herpesviridae Infections / Q000453:epidemiology* / Q000821:virology; D019288:Herpesvirus 8, Human / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000276:immunology; D016133:Polymerase Chain Reaction; D015995:Prevalence; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D000914:Antibodies, Viral; D000956:Antigens, Viral; D004279:DNA, Viral; D009687:Nuclear Proteins; C109540:latency-associated nuclear antigen